© 2022 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
January 14, 2022
The exciting therapies in the pipeline that are thought to target novel mechanisms in Waldenström macroglobulinemia.
What pharmacists need to know about BTK inhibitor drug activity, dosing, and interactions in Waldenström macroglobulinemia.
An overview of BTK inhibitors available as first-line therapy for Waldenström macroglobulinemia, and variables that impact treatment selection and the switching of agents throughout the course of therapy.
January 07, 2022
Recommendations for classifying and treating patients with progressive Waldenstrom macroglobulinemia.
The top considerations of hematologists and oncologists when selecting first-line treatment for patients with Waldenstrom macroglobulinemia.
December 23, 2021
What pharmacists need to know about the adoption of novel targeted therapies for Waldenstrom macroglobulinemia into regular clinical practice.